Type II secretory phospholipase a 2 and prognosis in patients with stable coronary heart disease: Mendelian randomization study

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Breitling, Lutz P ^a   Koenig, Wolfgang ^b   Fischer, Marcus ^c   Mallat, Ziad ^d   Hengstenberg, Christian ^c   Rothenbacher, Dietrich ^a,e   Brenner, Hermann ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SECRETORY PHOSPHOLIPASE A2; TYPE II SECRETORY PHOSPHOLIPASE A2; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; PHOSPHOLIPASE A2 GROUP II; PLA2G2A PROTEIN, HUMAN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGED; ALLELE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSAL ATTRIBUTION; COHORT ANALYSIS; CONFOUNDING VARIABLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; GENE; GENETIC POLYMORPHISM; HAZARD RATIO; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART REHABILITATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MENDELIAN RANDOMIZATION ANALYSIS; MULTIPLE REGRESSION; NUCLEOTIDE SEQUENCE; PLA2G2A GENE; PROGNOSIS; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE; BLOOD; CORONARY ARTERY DISEASE; ENZYMOLOGY; GENETICS; METABOLISM; MIDDLE AGED;

ADULT; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; COHORT STUDIES; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; GROUP II PHOSPHOLIPASES A2; HUMANS; MALE; MENDELIAN RANDOMIZATION ANALYSIS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS;

EID: 79960664419     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022318     Document Type: Article

References (28)

1. Boekholdt SM, Keller TT, Wareham NJ, Luben R, Bingham SA, et al. (2005) Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. Arterioscler Thromb Vasc Biol 25: 839-846.
2. Mallat Z, Benessiano J, Simon T, Ederhy S, Sebella-Arguelles C, et al. (2007) Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study. Arterioscler Thromb Vasc Biol 27: 1177-1183.
3. Kugiyama K, Ota Y, Takazoe K, Moriyama Y, Kawano H, et al. (1999) Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation 100: 1280-1284.
4. Mallat Z, Steg PG, Benessiano J, Tanguy ML, Fox KA, et al. (2005) Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol 46: 1249-1257.
5. Koenig W, Vossen CY, Mallat Z, Brenner H, Benessiano J, et al. (2009) Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease. Eur Heart J 30: 2742-2748.
6. Koenig W, Khuseyinova N, (2009) Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence. Cardiovasc Drugs Ther 23: 85-92.
7. Rosenson RS, (2009) Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease. Cardiovasc Drugs Ther 23: 93-101.
8. Jonsson-Rylander AC, Lundin S, Rosengren B, Pettersson C, Hurt-Camejo E, (2008) Role of secretory phospholipases in atherogenesis. Curr Atheroscler Rep 10: 252-259.
9. Rosenson RS, Gelb MH, (2009) Secretory phospholipase A2: a multifaceted family of proatherogenic enzymes. Curr Cardiol Rep 11: 445-451.
10. Mallat Z, Lambeau G, Tedgui A, (2010) Lipoprotein-associated and secreted phospholipases A in cardiovascular disease: roles as biological effectors and biomarkers. Circulation 122: 2183-2200.
11. Tietge UJ, Pratico D, Ding T, Funk CD, Hildebrand RB, et al. (2005) Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress. J Lipid Res 46: 1604-1614.
12. Sheehan NA, Didelez V, Burton PR, Tobin MD, (2008) Mendelian randomisation and causal inference in observational epidemiology. PLoS Med 5: e177.
13. Davey Smith G, Ebrahim S, (2003) 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32: 1-22.
14. Davey Smith G, Ebrahim S, (2004) Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol 33: 30-42.
15. Rothenbacher D, Koenig W, Brenner H, (2006) Comparison of N-terminal pro-B-natriuretic peptide, C-reactive protein, and creatinine clearance for prognosis in patients with known coronary heart disease. Arch Intern Med 166: 2455-2460.
16. Stephens M, Scheet P, (2005) Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet 76: 449-462.
17. Stephens M, Smith NJ, Donnelly P, (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68: 978-989.
18. Barrett JC, Fry B, Maller J, Daly MJ, (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265.
19. SAS Institute (2008) Statistical analysis software, release 9.2. Cary, NC SAS Institute.
20. Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD, (2005) Homocysteine and stroke: evidence on a causal link from mendelian randomisation. Lancet 365: 224-232.
21. R Foundation of Statistical Computing (2007) R v2.6.1. Vienna.
22. Wootton PT, Drenos F, Cooper JA, Thompson SR, Stephens JW, et al. (2006) Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study. Hum Mol Genet 15: 355-361.
23. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, et al. (2008) Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 359: 1897-1908.
24. Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, et al. (2009) Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA 302: 37-48.
25. Casas JP, Shah T, Cooper J, Hawe E, McMahon AD, et al. (2006) Insight into the nature of the CRP-coronary event association using Mendelian randomization. Int J Epidemiol 35: 922-931.
26. Brunner EJ, Kivimaki M, Witte DR, Lawlor DA, Davey Smith G, et al. (2008) Inflammation, insulin resistance, and diabetes--Mendelian randomization using CRP haplotypes points upstream. PLoS Med 5: e155.
27. Lee M, Hong KS, Chang SC, Saver JL, (2010) Efficacy of homocysteine-lowering therapy with folic Acid in stroke prevention: a meta-analysis. Stroke 41: 1205-1212.
28. Schunkert H, Samani NJ, (2008) Elevated C-reactive protein in atherosclerosis--chicken or egg? N Engl J Med 359: 1953-1955.